Company Description
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States.
The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule for the treatment of solid tumors, which is in preclinical trials.
It is also developing next generation T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
| Country | United States |
| Founded | 2000 |
| IPO Date | Oct 10, 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 341 |
| CEO | Scott Koenig |
Contact Details
Address: 9704 Medical Center Drive Rockville, Maryland 20850 United States | |
| Phone | 301 251 5172 |
| Website | macrogenics.com |
Stock Details
| Ticker Symbol | MGNX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001125345 |
| CUSIP Number | 556099109 |
| ISIN Number | US5560991094 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Scott Koenig M.D., Ph.D. | President, Chief Executive Officer and Director |
| James Karrels | Senior Vice President, Chief Financial Officer and Corporate Secretary |
| Dr. Stephen L. Eck M.D., Ph.D. | Senior Vice President of Clinical Development and Chief Medical Officer |
| Eric Blasius Risser | Chief Operating Officer |
| Dr. Thomas M. Spitznagel Ph.D. | Senior Vice President of Technical Operations |
| Dr. Ezio Bonvini M.D. | Senior Vice President of Research and Chief Scientific Officer |
| Jeffrey Stuart Peters J.D. | Senior Vice President, General Counsel and Corporate Compliance Officer |
| Beth Smith | Vice President, Controller and Treasurer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2025 | SCHEDULE 13G/A | Filing |
| Apr 11, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 11, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 20, 2025 | 8-K | Current Report |
| Mar 20, 2025 | 10-K | Annual Report |
| Feb 26, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 11, 2025 | SCHEDULE 13G | Filing |